Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Greater Transparency For Medicare Advantage Program Needed, MDMA Says

Executive Summary

Medtech industry groups call for greater transparency and oversight for Medicare Advantage plans.

You may also be interested in...



Industry Supports Transparency On Proposed CMS Prior Authorization Rule

Industry trade groups applaud CMS’s proposal to increase transparency for prior authorization approvals but are asking for expedited timeframes to provide care.

NAM’S Health Care AI Development Code Of Conduct Addresses Gaps In Current Principles

The National Academy of Medicine developed a code of conduct for health care AI development, as well as commitments for code implementation. 

Abbott Eagerly Awaits Damages Won From DexCom Patent Suit

Abbott’s trial win for patent infringement by DexCom’s CGM systems still doesn’t have information on damages awarded due a hung jury.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147642

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel